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The role of h e r 2-targeted  
therapies in women with  
h e r 2-overexpressing metastatic 
breast cancer
1.  INTRODUCTION
The human epidermal growth factor receptor 2 
(h e r 2) is a transmembrane tyrosine kinase receptor 
protein that is part of the h e r family of growth fac-
tor receptors (h e r1 to h e r4). The h e r 2 receptor is 
involved in cell–cell and cell–stroma communica-
tion, primarily through signal transduction involv-
ing the Ras/mitogen-activated protein kinase and 
phosphatidylinositol 3 kinase (p i3k)/Akt pathways 1. 
These signals ultimately promote cell proliferation, 
survival, and motility. Amplification of the h e r 2/neu 
gene and resulting overexpression of the h e r 2 protein 
occurs in approximately 20% of invasive primary 
breast cancers 2. The h e r 2 alteration in early-stage 
breast cancer is associated with more aggressive 
disease and a higher risk of relapse than is seen with 
h e r 2-negative cancers 3–7.
Trastuzumab is a monoclonal antibody that binds 
to the extracellular domain of h e r 2. Several mecha-
nisms of action underlie the antitumour effects of 
trastuzumab. Trastuzumab blocks h e r 2-activated cell 
signalling, thereby reducing cell proliferation and re-
storing ability to undergo apoptosis by inhibiting the 
p i3k/Akt pathway 1,8,9,a. The result is increased cellular 
sensitivity to chemotherapy and radiotherapy 10.
Trastuzumab has been shown to inhibit h e r 2-
regulated angiogenesis 8,11–13 and, in preclinical 
models, to recruit the immune system through antibody-
dependent cellular cytotoxicity, triggering activation 
of natural killer cell–mediated apoptosis 14–16. Tras-
tuzumab has also been shown to prevent the formation 
of p95
h e r 2 (a truncated active form of h e r 2), which 
may lead to inhibition of tumour development 8,17.
a  Migliaccio I, Gutierrez MC, Wu MF, et al. PI3 kinase activation 
and response to trastuzumab or lapatinib in h e r -2 overexpress-
ing locally advanced breast cancer (l a b c ). Presented at the 31st 
Annual San Antonio Breast Cancer Symposium; San Antonio, 
TX; December 10–14, 2008.
ABSTRACT
The role of targeted therapies in the treatment of 
women with breast cancer has been rapidly evolving. 
Trastuzumab, a monoclonal antibody against the hu-
man epidermal growth factor receptor 2 (h e r 2), was 
the first h e r 2-targeted therapy that clearly demon-
strated a significant clinical benefit for women with 
h e r 2-overexpressing metastatic breast cancer (m b c). 
However, in recent years it has become increasingly 
apparent that, when trastuzumab is used in the first-
line setting in combination with chemotherapy, most 
women eventually develop progressive disease. De-
termining the treatment options available to women 
who have progressed while on trastuzumab therapy 
has been hampered by a paucity of high-quality 
published data. In addition, with the standard use 
of trastuzumab in the adjuvant setting (for eligible 
h e r 2-positive patients), the role of anti-h e r 2 agents 
for patients who experience a breast cancer relapse 
has become a clinically relevant question. This manu-
script reviews current available data and outlines 
suggestions from a panel of Canadian oncologists 
about the use of trastuzumab and other h e r 2-targeted 
agents in two key m b c  indications:
Treatment for women with  •  h e r 2-positive m b c  
progressing on trastuzumab (that is, treatment 
beyond progression)
Treatment for women with  •  h e r 2-positive m b c  
recurring following adjuvant trastuzumab (that 
is, re-treatment)
The suggestions set out here will continue to 
evolve as data and future trials with trastuzumab and 
other h e r 2-targeted agents emerge.
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In pivotal first-line metastatic breast cancer (m b c) 
trials (Table i), the addition of trastuzumab to stan-
dard systemic chemotherapy treatment resulted in 
significantly improved time to disease progression, 
improved response rates, and an overall survival 
benefit (as compared with chemotherapy alone) 18–20. 
Consequently, single-agent trastuzumab following 
chemotherapy or trastuzumab in combination with 
chemotherapy is now considered standard treatment 
for m b c  patients who overexpress h e r 2. In clinical 
practice, trastuzumab is usually continued until 
disease progression.
There is considerable controversy regarding the 
potential clinical benefit of continuing trastuzumab 
after relapse—that is, therapy beyond disease progres-
sion—as a component of second and subsequent lines 
of systemic therapy. As well, with the approval and 
widespread incorporation of trastuzumab as a com-
ponent of adjuvant systemic therapy for h e r 2-positive 
early-stage breast cancers (stages i–iii), uncertainty 
remains regarding the potential role of trastuzumab-
based therapy upon relapse.
Data regarding these two clinical questions 
remain limited and primarily consist of nonrandom-
ized retrospective (Level 3) evidence. The goal of 
the present paper is to review the current evidence 
and to outline suggestions from a panel of Cana-
dian oncologists regarding the use of trastuzumab 
and other h e r 2-targeted therapies in two key m b c  
patient indications:
Treatment for women with  •  h e r 2-positive m b c  
progressing on trastuzumab (that is, treatment 
beyond progression)
Treatment for women with  •  h e r 2-positive m b c  
recurring following adjuvant trastuzumab (that 
is, re-treatment)
2.  DEVELOPMENT OF PANEL SUGGESTIONS
The authors of this paper met in Toronto for a one-day 
conference in June 2008. The panel reviewed results 
of the latest trials evaluating trastuzumab and other 
h e r 2-targeted agents in the neoadjuvant, adjuvant, and 
metastatic settings. Based on trial information, sug-
gestions were formulated for each setting. For m b c , 
a draft manuscript reviewing the current available 
data and outlining the suggestions from the panel was 
initially written by a medical writer (BW) and was re-
viewed and revised by four main panel members (SD, 
KP, ShV, and JL). The final manuscript was approved 
by the remaining seven panel members (JM, SuV, DR, 
SC, MC, JL, and LP). Published and presented clini-
cal trials results (available as of March 2009) were 
incorporated into the present document. Support for 
the initial meeting of the Canadian advisory panel 
and the development of the present manuscript was 
provided by an unrestricted educational grant from 
Hoffmann–La Roche Canada. The authors received 
an honorarium for attending the meeting, but not 
for writing the manuscript. The authors are solely 
responsible for the content of the manuscript, with 
no restrictions set by the sponsor.
3.  TRIALS IN MBC
Two major pivotal trials involving more than 650 
women with h e r 2-positive m b c  have examined the 
t a b l e  i   Efficacy results from pivotal first-line metastatic breast cancer trials
Clinical 
endpoint
Trial arms 
Slamon et al., 2001 18 
(n=469)
Trial arms 
Marty et al., 2005 and 2006 19,20 
(n=186)
Trastuzumab AND 
[paclitaxel OR 
(anthracycline AND 
cyclophosphamide)]
Paclitaxel OR 
(anthracycline AND 
cyclophosphamide)
Trastuzumab AND 
docetaxel
Docetaxel 
alone
Median o r r  (%) 50 32 61 34
p<0.001 p=0.0002
Median d r  (months) 9.1 6.1 11.7 5.7
p<0.001 p=0.009
Median t t p (months) 4.7 4.6 11.7 6.1
p<0.001 p=0.0001
Median o s  (months) 25.1 20.3 31.2 22.7
p=0.046 p=0.0325a
a     Trial survival results were updated at the 2006 San Antonio Breast Cancer Symposium. The superior survival benefit for trastuzumab plus 
docetaxel over docetaxel alone was maintained (31.2 months vs. 22.7 months); however, the survival difference was no longer significant 
(p = 0.0876), perhaps because most of the patients randomized to docetaxel alone (57%) subsequently crossed over to receive trastuzumab.
o r r  = objective response rate; d r  = duration of response; t t p = time to progression; o s  = overall survival.PRACTICE GUIDELINE SERIES
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role of trastuzumab in combination with systemic 
chemotherapy as compared with chemotherapy alone 
in the first-line setting 18–20. In both studies, although 
different chemotherapeutic regimens were used, the 
addition of trastuzumab, as compared with chemo-
therapy alone, significantly prolonged time to disease 
progression, increased response rate, prolonged 
duration of response, and increased overall survival 
benefit (Table i).
Several small, retrospective case–cohort studies 
have examined the role of continuing trastuzumab 
beyond progression in second- and subsequent-line 
therapy with various chemotherapy partners. Overall 
response rates ranged from 18% to 50% in the sec-
ond line, 14.3% to 38.1% in the third line, 19.2% to 
20% in the fourth line, and less than 10% in fifth-line 
trastuzumab-based regimens. Time to progression 
was reported as 4.0–9.0 months in the second line, 
3.5–9 months in the third line, 4–4.9 months in the 
fourth line, and approximately 4 months in fifth-line 
trastuzumab-based regimens (Table ii) 21–29.
Similar results of continuing trastuzumab with 
various chemotherapy partners beyond progression 
in women with m b c  have been observed in prospec-
tive phase ii trials, although data remain limited. 
Across studies, overall response rates of 11%–50% 
t a b l e  ii   Response rates of trastuzumab in combination with chemotherapy in women with metastatic breast cancer progressing on trastu-
zumab: retrospective and case–cohort studies
Reference Patientsa Therapy line
(n) Second Third Fourth Fifth
O r r t t p O r r t t p O r r t t p O r r t t p
(%) (months) (%) (months) (%) (months) (%) (months)
Tokajuk et al., 2006 21 14 50 5.1 — — — — — —
(docetaxel, vinorelbine, cisplatin, capecitabine, etoposide, gemcitabine, and trastuzumab)
Stemmler et al., 2005 22 23 39.1 — — — — — — —
(taxane, vinorelbine, or other chemotherapy, and trastuzumab)
Gelmon et al., 2004 23 65 32 — — — — — — —
(taxane, or vinorelbine and trastuzumab, or trastuzumab alone)
García-Saénz et al., 2006 24 47 (2nd line) 29.8 4 38.1 4 20 4 0b n r
21 (3rd line)
10 (4th line)
(chemotherapy and trastuzumab)
Metro et al., 2007 25 37 (2nd line) 29 6.7 0 4 0 4.5 — —
16 (3rd line)
9 (4th line)
(chemotherapy and trastuzumab)
Fountzilas et al., 2003 26 80 (2nd line) 23.8 5.2 14.3 3.5 19.2 4.9 8.3 3.9
49 (3rd line)
26 (4th line)
12 (5th line)
(vinorelbine or gemcitabine and trastuzumab)
Adamo et al., 2007 27 26 (2nd line) 23 9 22 9c — — — —
9 (3rd line)
(vinorelbine, taxane, pegylated liposomal doxorubicin, or gemcitabine and trastuzumab)
Montemurro et al., 2006 28 40 18 — — — — — — —
(vinorelbine, taxanes, liposomal doxorubicin, capecitabine, letrozole, or tamoxifen and 
trastuzumab)
Fabi et al., 2008 29 59 27 6.7 — — — — — —
(chemotherapy and trastuzumab)
a   Those who received trastuzumab treatment beyond progression (in the second line, unless otherwise stated).
b   Stable disease 60%.
c   Reported for third-line treatment and beyond.
o r r  = overall response rate; t t p = time to progression; n r  = not reported.DENT et al.
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were observed after a second-line trastuzumab-based 
regimen, with a greater than 60% response rate ob-
served with one third-line trastuzumab-based regimen 
(Table iii). Time to progression ranged from 6 months 
to 8 months in second-line and 9 months in third-line 
trastuzumab-based regimens (Table iii) 30–36.
The French Hermine trial, a prospective obser-
vational study in women who had h e r 2-positive 
m b c , contributed intriguing survival data in the set-
ting of progression 37,38. A total of 623 patients were 
enrolled, of whom 221 (cohort A) received first-line 
trastuzumab-based therapy (that is, with paclitaxel, 
docetaxel, vinorelbine, or capecitabine) and 117 
(cohort B) received trastuzumab-based therapy as 
part of second-line treatment 38. After 2 years of 
follow-up, significantly longer overall survival was 
observed in patients treated with first-line trastuzumab 
(cohort A) as compared with those who discontinued 
trastuzumab after initial progression (Table iv). For 
patients who continued trastuzumab as a component 
of second-line therapy (cohort B), overall survival 
from the first trastuzumab treatment was again longer 
than it was in patients who discontinued trastuzumab 
(Table iv). Given the nonrandomized nature of the 
t a b l e  iii   Response rates for trastuzumab in combination with chemotherapy in women with metastatic breast cancer progressing on trastu-
zumab, prospective phase ii trials
Reference Patientsa Therapy line
(n) Second Third
O r r t t p O r r t t p
(%) (months) (%) (months)
Tripathy et al., 2004 30 93 11 — — —
(chemotherapy and trastuzumab)
Morabito et al., 2006 31 7 29 — — —
(vinorelbine, gemcitabine, and trastuzumab)
Orlando et al., 2006 32 11 18 6 — —
(cyclophosphamide, methotrexate, and trastuzumab)
Del Bianco et al., 2006 33 8 (2nd line) 50 8 62.5 9
8 (3rd line)
(chemotherapy and trastuzumab)
Bartsch et al., 2007 34 40 20b 8b — —
(capecitabine and trastuzumab)
Bachelot et al., 2007 35 17 29 — — —
(vinorelbine and trastuzumab)
Modi et al., 2007 36 20 25 — — —
(tanespimycin and trastuzumab)
a   Those who received trastuzumab treatment beyond progression (in the second line, unless otherwise stated).
b   Reported for second-line treatment and beyond.
o r r  = overall response rate; t t p = time to progression.
t a b l e  iv   Summary of efficacy data from French Hermine cohort study 38
Efficacy endpoint Therapy line
First 
(n=177a)
Second 
(n=117)
Continued 
trastuzumab 
(n=107)
Discontinued 
trastuzumab 
(n=70)
Continued 
trastuzumab 
(n=87)
Discontinued 
trastuzumab 
(n=30)
Median o s  (months) From initiation of trastuzumab Not reachedb 16.8 27.2 15.6
From date of progression 21.3 4.6 15.5 11
o s  at 2 years (%) From initiation of trastuzumab 73.7 24.7 55.7 41.8
a   Follow-up data are available for only 177 of the 221 patients who received first-line trastuzumab-based therapy.
b   After a median follow-up of 27.8 months.
o s  = overall survival.PRACTICE GUIDELINE SERIES
29
Cu r r e n t On C O l O g y —VO l u m e  16, nu m b e r 4
study and the potential biases involved in the selec-
tion of patients who received second-line therapy, the 
foregoing results must be interpreted with caution. 
It is feasible that underlying patient characteristics 
could have contributed to the observed improve-
ment in overall survival in patients who were able to 
continue to receive trastuzumab therapy at the time 
of disease progression.
3.1  Randomized Clinical Trials
A recently published study addressed the question 
of continuing trastuzumab beyond progression after 
first-line treatment39 (Table V). This prospective 
phase iii trial compared capecitabine plus trastu-
zumab with capecitabine alone in patients with 
locally advanced or metastatic breast cancer with 
disease progression during trastuzumab treatment. 
Patients could have received up to one prior chemo-
therapy regimen for m b c . Patients were required to 
be trastuzumab-free for fewer than 6 weeks, to have 
been taking trastuzumab for at least 12 weeks, and 
to have a baseline left ventricular ejection fraction 
of 50% or better. A total of 156 (of a planned 482) 
patients were accrued. During the recruitment phase 
of the study, lapatinib was registered by the U.S. 
Food and Drug Administration for the indications 
being tested, and on the advice of the Independent 
Data Monitoring Committee, this study was termi-
nated prematurely. The primary objective was time 
to progression; secondary objectives were safety, 
objective response rates, clinical benefit rates, and 
overall survival 39. Patients received capecitabine 
(2500 mg/m2) for 14 days of a 21-day cycle, and 
trastuzumab (6 mg/kg) was administered in 3-week 
cycles. Compared with capecitabine alone, the ad-
dition of trastuzumab to capecitabine resulted in 
significant improvements in time to progression 
(8.2 months vs. 5.6 months; hazard ratio: 0.69; 95% 
confidence interval: 0.48 to 0.9; p = 0.0338), with 
significant improvements in overall response rates 
(48.1% vs. 27.0%, p = 0.0115) and clinical benefit 
rate (75.3% vs. 54.0%, p = 0.0068).
Median overall survival was not statistically 
different (25.5 months vs. 20.4 months, p = 0.257). 
No unexpected toxicities were observed. In the tras-
tuzumab-containing arm, single cases of congestive 
heart failure, tachyarrhythmia, hypertension, and a 
drop to below 40% or a 10% decline from baseline in 
left ventricular ejection fraction were observed.
3.2  Other Targeted Strategies for Treatment Beyond 
Progression
A number of other agents targeting h e r 2 and other 
members of the epidermal growth factor receptor 
family have been evaluated as single agents or in 
combination with other chemotherapy partners. These 
include lapatinib and pertuzumab.
The role of lapatinib, a tyrosine kinase inhibitor 
that inhibits both h e r1 and h e r 2, was investigated in a 
prospective randomized phase iii clinical trial. Women 
with h e r 2-positive m b c  who had progressed on trastu-
zumab (n = 324) and who had received anthracyclines 
and taxanes, were randomized to receive capecitabine 
alone (2500 mg/m2 days 1–14, every 3 weeks) or 
capecitabine (2000 mg/m2 days 1–14, every 3 weeks) 
with lapatinib (1250 mg/m2 twice daily, days 1–14, 
every 3 weeks) 40,41. The primary endpoint was time 
to progression. Secondary endpoints included progres-
sion-free survival, overall survival, clinical benefit, 
partial response rate, and safety. Women assigned 
to the combination arm experienced a significantly 
longer time to progression (27 weeks vs. 19 weeks, 
p = 0.00013) than did those taking capecitabine alone. 
Overall response rates were higher in the combina-
tion arm (24% vs. 14%, p = 0.017). The hazard ratio 
for overall survival in the combination arm (versus 
capecitabine alone) was 0.78 (95% confidence interval: 
0.55 to 1.12; p = 0.177; Table v i). Based on these data, 
the combination of lapatinib with capecitabine was 
t a b l e  v   Summary of efficacy data from the German Breast Group 
26 trial
Clinical 
endpoint
Trial arms 
von Minckwitz et al., 2009 39 
(n=152)
Trastuzumab AND 
capecitabine
Capecitabine 
alone
t t p (months) 8.2 5.6
p=0.0338
o r r  (%) 48.1 27.0
p=0.0115
c b r  (%) 75.3 54.0
p=0.0068
o s  (months) 25.5 20.4
p=0.257
t t p = time to progression; o r r  = overall response rate; c b r  = clinical 
benefit rate; o s  = overall survival.
t a b l e  v i    Summary of efficacy data from trials by Geyer et al.
Clinical 
endpoint
Trial arms 
Geyer et al., 2006 and 2007 40,41 
(n=324)
Lapatinib AND 
capecitabine
Capecitabine 
alone
t t p (weeks) 27a 19a
p=0.00013a
p f s (%) 8.4 4.1
p<0.001
o r r  (%) 24a 14a
p=0.017a
c b r  (%) 44 29
n r
o s  (months) n r n r
p=0.177a
a   Based on updated data presented in 2007.
t t p = time to progression; p f s = progression-free survival; o r r  = 
objective response rate; c b r = clinical benefit rate; n r  = not reported; 
o s  = overall survival.DENT et al.
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approved by the U.S. Food and Drug Administration 
for patients with advanced or metastatic h e r 2-positive 
breast cancer who have received prior therapy with an 
anthracycline, a taxane, and trastuzumab.
Lapatinib was recently approved by Health Canada 
(May 14, 2009) and is indicated in combination with 
capecitabine for the treatment of patients with advanced 
or metastatic breast cancer whose tumours overexpress 
h e r 2. Eligible patients should have progressed on tax-
anes, anthracyclines, and trastuzumab before the start 
of the lapatinib and capecitabine combination. Health 
Canada approval was based on improvement in time 
to progression; no significant improvement in overall 
survival was observed.
O’Shaughnessy et al. examined trastuzumab and 
lapatinib combinations versus lapatinib alone in wom-
en with heavily pretreated h e r 2-positive m b c  (n = 296) 
progressing on trastuzumab therapy. The primary 
endpoint was progression-free survival; the second-
ary endpoints were clinical benefit rate at 24 weeks, 
response rate, and overall survival. Patients in the 
intent-to-treat population who received combination 
therapy experienced a significantly longer median 
progression-free survival (12.0 weeks vs. 8.4 weeks, 
p = 0.029) and a significantly better clinical benefit 
rate (25.2% vs. 13.2%, p = 0.02). The differences in 
response rate (10.3% vs. 6.9%, p = 0.46) and median 
overall survival time (51.6 weeks vs. 39.0 weeks, 
p = 0.106) were not statistically significant 42.
Pertuzumab, another humanized monoclonal 
antibody developed to target a different domain of 
the h e r 2 receptor, has been studied in combination 
with trastuzumab for patients with h e r 2-positive m b c  
and disease progression on, or subsequent to, trastu-
zumab therapy with two or more prior chemotherapy 
regimens 43–46. In a phase ii open-label single-arm 
study, a clinical benefit rate of 50.0% and an objec-
tive response rate of 24.2% (including 16.7% partial 
response and 7.6% complete response) were observed 
in 66 evaluable patients 46. No clinically significant 
cardiac events were observed.
3.3  MBC After Adjuvant Trastuzumab (Re-treatment)
There are currently no published clinical trials to guide 
clinicians in the management of women with h e r 2-
positive m b c  who relapse after receiving adjuvant tras-
tuzumab. A number of actively recruiting phase ii and iii 
studies are addressing this important clinical issue.
The r h e a (Retreatment After Herceptin Adju-
vant) study is a nonrandomized phase ii trial that is 
examining the efficacy of trastuzumab therapy alone 
(cohort A) or with docetaxel or paclitaxel (cohort B) 
in patients who have relapsed 6 months or more after 
completion of at least 10 months of adjuvant trastu-
zumab. The choice of cohort will be made for each 
patient by the investigator, in accordance with the 
investigator’s clinical practice. The planned size for 
each cohort is 40 patients 47.
Three ongoing phase iii trials are evaluating 
first-line systemic therapy regimens for women with 
h e r 2-positive m b c  who may or may not have received 
adjuvant trastuzumab. Although these trials do not 
specifically address the potential benefit of the ad-
dition of trastuzumab to the chemotherapy regimen 
(versus the absence of trastuzumab), the results of 
such studies may provide some insight into the role 
of targeted therapy in this setting.
The c l e o pat r a trial is examining the efficacy and 
safety of trastuzumab and docetaxel with or without 
pertuzumab as first-line chemo-biologic therapy in 
patients with h e r 2-positive m b c , with a disease-free in-
terval of 12 months or more after adjuvant trastuzumab. 
The primary endpoint is progression-free survival; 
secondary endpoints are overall survival, response rate, 
and safety. The targeted sample size is 800 48.
The a v e r e l  trial is designed to assess the efficacy 
and safety of first-line trastuzumab and docetaxel with 
or without bevacizumab in patients with h e r 2-positive 
locally recurrent or metastatic breast cancer who have 
not received prior chemotherapy or radiotherapy for 
their metastatic disease. Patients will be stratified by 
prior adjuvant and neoadjuvant taxane chemotherapy 
and prior adjuvant trastuzumab therapy. Patients will 
be stratified by prior adjuvant or neoadjuvant taxane 
chemotherapy and prior adjuvant trastuzumab therapy. 
Patients must have completed adjuvant trastuzumab 
therapy 6 months or more before enrolment. The pri-
mary endpoint is progression-free survival; secondary 
endpoints are overall survival, overall response, dura-
tion of response, time to treatment failure, quality of 
life, and safety. The target sample size is 410 49.
The m a .31 (c o m p l e t e) trial being undertaken by 
the National Cancer Institute of Canada Clinical Tri-
als Group is an international phase iii trial examining 
the efficacy and safety of first-line taxane-based che-
motherapy combined with lapatinib (or trastuzumab) 
in patients with h e r 2-positive metastatic disease. 
Patients are required to have had at least a 12-month 
interval from prior chemotherapy or h e r 2-targeted 
therapy in the adjuvant or neoadjuvant setting. The 
primary endpoint is progression-free survival; sec-
ondary endpoints include overall survival, incidence 
rates of and time to central nervous system metastases 
at the time of progression, overall response rate, clini-
cal benefit response rate, adverse event profile, quality 
of life, clinical outcomes using biomarkers, and health 
economics (including healthcare utilization and health 
utilities). The target sample size is 600 50.
3.4  Other Targeted Therapies
A variety of other novel targeted therapies are cur-
rently under investigation in women with h e r 2-overex-
pressing m b c  who may have received adjuvant 
trastuzumab-based therapy (that is, those who present 
with de novo metastatic disease) or for women who have 
progressed while receiving trastuzumab-based therapy PRACTICE GUIDELINE SERIES
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for metastatic disease (second- or subsequent-line set-
ting). In a phase ii trial, trastuzumab-m c c -d m1, a toxin-
conjugated version of trastuzumab 51, appears to offer 
improved efficacy and reduced toxicity over unconju-
gated trastuzumab in heavily pre-treated patients 52. An 
ongoing phase iii trial is currently evaluating trastu-
zumab-m c c -d m1 in comparison with the combination 
of capecitabine and lapatinib in patients with h e r 2-
positive locally advanced or metastatic breast cancer 
who have received prior trastuzumab-based therapy 53.
The mammalian target of rapamycin, mt o r , is 
a central regulator of G1 cell-cycle protein synthe-
sis that precedes commitment to normal cellular 
replication. Inhibition of mt o r  has been shown to 
have antiproliferative activity in breast cancer by 
deregulation of the p i3k/Akt pathway 54–56. One mt o r  
inhibitor, deforolimus, is now being tested in combi-
nation with trastuzumab in a single-arm phase ii trial 
involving h e r 2-positive trastuzumab-refractory m b c  
patients. For eligible patients, at least 4 weeks must 
have elapsed since earlier investigational therapy, 
chemotherapy, or radiotherapy 57. The t r i o-018 inter-
national phase iii study is evaluating the addition of 
everolimus (or placebo) to standard trastuzumab and 
weekly paclitaxel in the treatment of h e r 2-positive 
advanced breast cancer 58.
Histone deacetylase is another anticancer target 
that controls gene expression through transcription 
regulation 59,60. Panobinostat, an inhibitor of his-
tone deacetylase 61, is being studied in a single-arm 
phase iib/iia trial in combination with trastuzumab 
for h e r 2-positive m b c  patients who have progressed 
during or after trastuzumab treatment 62. Panobin-
ostat is also being studied as monotherapy in the 
t r i o-016 study 63.
Heat shock protein 90 (Hsp90) is a chaperone 
protein that enables cancer cell survival 64. The Hsp90 
inhibitor IPI-504 is being investigated in a single-
arm phase ii trial in combination with trastuzumab 
for patients with pretreated, locally advanced, or 
metastatic h e r 2-positive breast cancer. Patients must 
have received at least two earlier regimens, with 
trastuzumab being a component in at least one (not 
including adjuvant regimens, unless progression on 
adjuvant treatment occurred) 65.
The selective angiopoietin 1 and 2–neutralizing 
“peptibody” AMG 386 inhibits angiogenesis by pre-
venting interaction of angiopoietins with Tie2 recep-
tors 66. This agent is currently being studied in a phase i 
setting combining escalating doses of AMG 386 with 
paclitaxel and trastuzumab, and escalating doses of 
AMG 386 with capecitabine and lapatinib 67.
4.  DISCUSSION
4.1  Treatment Beyond Progression
Although retrospective case–cohort and prospec-
tive phase ii clinical trials (Level 3 evidence) have 
demonstrated safety and suggested possible clinical 
benefit from the continuation of trastuzumab beyond 
progression after first-line therapy in women with 
h e r 2-positive m b c , it has been impossible to support 
the use of this strategy without higher quality (Lev-
el 1) evidence. The uncertainty of this therapeutic 
approach has been compounded by a lack of under-
standing of the mechanism of resistance to targeted 
therapies in h e r 2-positive m b c . At the present time, a 
good definition of resistance from a mechanistic point 
of view is not available, leaving practitioners to rely 
on a clinical definition based on disease progression 
in relation to the targeted therapy. This area remains 
one of active, ongoing research.
The prospective randomized controlled trial 
conducted by the German Breast Group (g b g  26) 
demonstrated the clinical benefit of continuing tras-
tuzumab with another chemotherapy partner (time 
to progression: 8.2 months vs. 5.6 months) 39. The 
absence of an overall survival advantage should 
not be a deterrent to the use of trastuzumab beyond 
first-line progression, because time to progression 
is an endpoint worthy of consideration. In addition, 
given that g b g  26 was prematurely stopped and that 
the targeted sample size was not reached, it is pos-
sible that the study was underpowered to detect a 
survival difference.
Two randomized phase iii trials have examined 
the role of combining (lapatinib–trastuzumab) or 
switching (trastuzumab to lapatinib plus capecitabi-
ne) targeted therapies in women with h e r 2-positive 
m b c . Although these two studies do not directly 
address the question of continuing trastuzumab 
beyond progression (no arm without trastuzumab), 
the results support the contention that, in this popula-
tion, continuing an anti-h e r 2 targeted therapy may 
be reasonable.
Panel Suggestion:   It is highly unlikely that addition-
al studies examining the specific role of trastuzumab 
combined with “second-line” chemotherapy will be 
forthcoming for women with h e r 2-positive m b c  who 
have progressed on trastuzumab. The available evi-
dence, including data from prospective randomized 
controlled trials, seems to support the continuation 
of h e r 2-targeted therapy with trastuzumab or with 
lapatinib in combination with capecitabine. Despite 
these panel suggestions, the modest clinical benefits 
observed with this approach should encourage further 
research and participation in clinical trials for this 
patient population.
4.2  Re-treatment
No randomized clinical data support the use of tras-
tuzumab or other anti-h e r 2 therapies in women with 
h e r 2-positive m b c  who have received trastuzumab in 
the adjuvant setting. Several clinical trials are cur-
rently addressing this important clinical issue.DENT et al.
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Panel Suggestion:   In the absence of data, and given 
the benefits seen in m b c  patients who continue tras-
tuzumab beyond progression, it would seem reason-
able to consider re-treatment for patients exposed to 
adjuvant trastuzumab who have relapsed 6 months or 
more after adjuvant therapy. Participation in clinical 
trials for this patient population is encouraged.
5.  CONCLUSIONS
The authors of this manuscript developed treatment 
suggestions based on a review of the literature regard-
ing treatment options for women with h e r 2-positive 
m b c . The role of targeted therapies in this patient 
population will continue to evolve with the comple-
tion and publication of ongoing clinical trials.
5.1  Date of Author Suggestions
The panel suggestions were completed in March 
2009.
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